| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.01 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.068 | 0.02 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.02 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.02 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.02 |